| Literature DB >> 34381527 |
Oliver Deberu1,2, Bernard Nkrumah3, Augustina Angelina Sylverken4, David Sambian2, Godfred Acheampong2, John Amuasi5, Azure Stebleson1, Daron Agboyie1, Monica Yenbaree1, Sylvester Mensah1, Abaifa Dombadoh1, Dorcas Ohui Owusu6, Abass Abdul-Karim1, Michael Owusu2,7.
Abstract
INTRODUCTION: lower respiratory tract infections (LRTIs) are infections involving the trachea, primary bronchi and lungs. People with LRTIs typically experience coughs as the primary symptoms; however, shortness of breath, weakness, fever and fatigue may be coupled with the cough. It is common among the aged, children under five and the immune-suppressed. Persons with symptoms suggestive of pulmonary tuberculosis (TB) may have tuberculosis, other respiratory tract infection or co-infection of tuberculosis and other respiratory pathogens. This study aimed to identify the presence of pathogens in sputum of suspected tuberculosis cases and their antimicrobial resistance patterns.Entities:
Keywords: Sputum; Tamale Public Health Laboratory; culture; infection; lower respiratory tract; pathogens; tuberculosis
Mesh:
Substances:
Year: 2021 PMID: 34381527 PMCID: PMC8325465 DOI: 10.11604/pamj.2021.38.383.26333
Source DB: PubMed Journal: Pan Afr Med J
demographic characteristics of participants
| Variable | Frequency (n = 264), n (%) | ||
|---|---|---|---|
| Positive cultures | Negative cultures | p-value | |
| Male | 61 (23.1) | 69 (26.1) | 0.89 |
| Female | 64 (24.2) | 70 (26.5) | |
| ≤20 | 13 (4.9) | 14 (5.3) | 0.58 |
| 21 - 30 | 15 (5.7) | 14 (5.3) | |
| 31 - 40 | 14 (5.3) | 21 (8.0) | |
| 41+ | 83 (31.4) | 74 (28.0) | |
| Yes | 96 (36.4) | 90 (34.1) | 0.03 |
| No | 29 (11.0) | 49 (18.6) | |
| Sputum | 124 (47.0) | 136 (51.5) | 0.37 |
| Gastric lavage | 1 (0.4) | 3 (1.1) |
Figure 1distribution of isolates recovered from sputum
lower respiratory tract infections among TB positive and negative subjects
| Isolates | TB positive (n = 12) | % | TB negative (n = 174) | % | Total (n = 186) | % |
|---|---|---|---|---|---|---|
| 0 | 0 | 27 | 15.5 | 27 | 14.5 | |
| 2 | 17 | 13 | 7.5 | 15 | 8.1 | |
| 1 | 8 | 13 | 7.5 | 14 | 7.5 | |
| 1 | 8 | 11 | 6.3 | 12 | 6.5 | |
| 1 | 8 | 13 | 7.5 | 14 | 7.5 | |
| 0 | 0 | 5 | 2.9 | 5 | 2.7 | |
| 0 | 0 | 2 | 1.1 | 2 | 1.1 | |
| 0 | 0 | 1 | 0.6 | 1 | 0.5 | |
| 0 | 0 | 1 | 0.6 | 1 | 0.5 | |
| 0 | 0 | 1 | 0.6 | 1 | 0.5 | |
| 1 | 8 | 3 | 1.7 | 4 | 2.2 | |
| Total | 6 | 50.0 | 90 | 51.7 | 96 | 51.6 |
Figure 2monthly trend of patients enrolled and isolates recovered throughout the study period
rate of antimicrobial resistance among commonly isolated bacteria
| % resistance | ||||||
|---|---|---|---|---|---|---|
| Antibiotics | Klebsiella spp. (n=35) | Pseudomonas spp. (n=19) | Acinetobacter baumannii (n=16) | Escherichia coli (n=18) | Moraxella catarrhalis (n=18) | Enterobacter cloacae (n=8) |
| GEN | 22.9 | 26.3 | 0 | 50.0 | 5.6 | 0 |
| CIP | 11.4 | 5.3 | 25.0 | 38.9 | 22.2 | 12.5 |
| CTX | 25.7 | 15.8 | 43.8 | 22.2 | - | 12.5 |
| CRO | 40.0 | 10.5 | 62.5 | 61.1 | 5.6 | 37.5 |
| CZM | 28.6 | 5.3 | 6.3 | 38.9 | 11.1 | - |
| AZM | 11.4 | 5.3 | - | 22.2 | - | 12.5 |
| AMK | 0 | 5.3 | - | 5.6 | 27.8 | - |
| AMC | 25.7 | 15.8 | 50.0 | 61.1 | - | 87.5 |
| SXT | 11.4 | 10.5 | 6.3 | 22.2 | 22.2 | 37.5 |
| MEM | 0 | 0 | 6.3 | 0 | - | - |
GEN: gentamicin; CIP: ciprofloxacin; CRO; ceftriaxone; CZM: ceftazidime; AZM: azithromycin; AMK: amikacin; AMC: amoxicillin/clavulanic acid; SXT: trimethoprim/sulfamethoxazole; MEM: meropenem; CTX: cefotaxime